# COVID-19: a vascular nightmare unfolding

## TL;DR

This paper reviews how immune inflammation contributes to blood clots in COVID-19 and updates on drug trials and guidelines for prevention.

## Contribution

The paper offers a comprehensive review of thrombosis mechanisms and pharmacological prevention strategies in COVID-19.

## Key findings

- Immune inflammation is a key driver of thrombosis in COVID-19 patients.
- Pharmacological interventions are being tested to prevent thrombosis in these patients.
- Guidelines for thrombosis prevention are evolving with new research findings.

## Abstract

The emergence of COVID-19 has been associated with an increased risk of arteriovenous thrombosis, with immune inflammation playing a significant role in the pathogenesis of thrombosis. Numerous drug-related clinical trials have been undertaken to prevent thrombosis, and guidelines for its prevention and treatment are continuously evolving as our understanding of the disease progresses. This article provides a comprehensive review of the mechanisms underlying thrombosis in COVID-19 patients, as well as the advancements in clinical trials and guidelines for thrombosis prevention with pharmacological interventions.